Nurix Therapeutics, Inc. (NRIX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Oct 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NRIX SEC filings page.
Nurix Therapeutics, Inc. (NRIX) reported $701.9M in revenue over the twelve months to Aug 31, 2026, up 738.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Nurix is funding a development-stage business: revenue is growing, but R&D expansion is pushing losses and cash use higher.
Revenue rose from$54.5M in FY2024 to$84.0M in FY2025, while R&D increased faster than sales. That mismatch matters because operating cash outflow expanded to$249.5M while free cash flow reached-$263.5M , indicating additional investment translated into cash consumption rather than merely accounting expense.
A 7.0x current ratio alongside
Operating margin improved from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Nurix Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nurix Therapeutics, Inc. held $592.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $249.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Nurix Therapeutics, Inc. scores 54/100 among other emerging companies.
Nurix Therapeutics, Inc. had 103M shares outstanding at the end of fiscal year 2025, against 76M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Nurix Therapeutics, Inc. scores 21/100 among other emerging companies.
Nurix Therapeutics, Inc. spent $316.9M on research and development in fiscal year 2025, which was 85.7% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Nurix Therapeutics, Inc. scores 100/100 among other emerging companies.
Nurix Therapeutics, Inc. reported revenue of $84.0M in fiscal year 2025, against $54.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Nurix Therapeutics, Inc. scores 49/100 among other emerging companies.
Nurix Therapeutics, Inc.'s operations used $249.5M of cash in fiscal year 2025, against $172.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Nurix Therapeutics, Inc. scores 11/100 among other emerging companies.
Nurix Therapeutics, Inc.'s cash, cash equivalents and investments came to $592.9M at the end of fiscal year 2025, against $149.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Nurix Therapeutics, Inc. scores 86/100 among other emerging companies.
Nurix Therapeutics, Inc. scores 8.00, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.6B) relative to total liabilities ($149.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nurix Therapeutics, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Nurix Therapeutics, Inc. reported a net loss of $264.5M while operations used $249.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Nurix Therapeutics, Inc. generated $673.1M in revenue in Q3 2026. This represents an increase of 8426.3% from the same quarter a year earlier. Against the prior quarter it is up 7342.9%.
Nurix Therapeutics, Inc.'s EBITDA was $561.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 728.5% from the same quarter a year earlier. Against the prior quarter it is up 710.8%.
Nurix Therapeutics, Inc. reported $549.8M in net income in Q3 2026. This represents an increase of 736.2% from the same quarter a year earlier. Against the prior quarter it is up 714.1%.
Nurix Therapeutics, Inc. earned $4.73 per diluted share (EPS) in Q3 2026. This represents an increase of 559.2% from the same quarter a year earlier. Against the prior quarter it is up 684.0%.
Cash & Balance Sheet
Nurix Therapeutics, Inc. generated $614.2M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 1122.1% from the same quarter a year earlier. Against the prior quarter it is up 723.5%.
Nurix Therapeutics, Inc. held $720.2M in cash as of Q3 2026; long-term debt is not reported for that period.
Not reported for Q3 2026.
Margins & Returns
Nurix Therapeutics, Inc.'s operating margin was 83.1% in Q3 2026, reflecting core business profitability. No change is given against Q3 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Nurix Therapeutics, Inc.'s net profit margin was 81.7% in Q3 2026, showing the share of revenue converted to profit. No change is given against Q3 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Nurix Therapeutics, Inc.'s ROE was 56.8% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is up 80.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 79.0 percentage points.
Not reported for Q3 2026.
Capital Allocation
Nurix Therapeutics, Inc. invested $79.3M in research and development in Q3 2026. This represents a decrease of 8.0% from the same quarter a year earlier. Against the prior quarter it is down 9.6%.
Nurix Therapeutics, Inc. invested $1.4M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 48.7% from the same quarter a year earlier. Against the prior quarter it is down 28.1%.
Not reported for Q3 2026.
NRIX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $673.1M+8426.3% | $9.0M-79.5% | $6.3M-66.1% | $13.6M+2.2% | $7.9M-37.3% | $44.1M+264.3% | $18.5M+11.3% | $13.3M-12.4% |
| R&D Expenses | $79.3M-8.0% | $87.7M+12.2% | $84.1M+20.8% | $83.0M+23.5% | $86.1M+55.2% | $78.1M+59.6% | $69.7M+39.3% | $67.2M+35.2% |
| SG&A Expenses | $34.4M+161.1% | $15.6M+9.2% | $14.6M+25.4% | $13.6M+27.3% | $13.2M+12.3% | $14.3M+22.0% | $11.7M-1.2% | $10.7M-0.6% |
| Operating Income | $559.5M+712.2% | -$94.2M-95.0% | -$92.5M-47.1% | -$83.1M-28.5% | -$91.4M-67.3% | -$48.3M+0.4% | -$62.9M-39.0% | -$64.7M-42.6% |
| EBITDA | $561.6M+728.5% | -$91.9M-99.5% | -$90.3M-49.2% | -$81.0M-30.4% | -$89.4M-71.1% | -$46.1M+0.3% | -$60.5M-40.2% | -$62.1M-43.1% |
| Income Tax | $13.6M | -$271K-135.7% | $0 | $0-100.0% | $0-100.0% | $760K+744.4% | $0-100.0% | $8K |
| Net Income | $549.8M+736.2% | -$89.5M-106.0% | -$87.2M-54.7% | -$78.2M-33.6% | -$86.4M-76.5% | -$43.5M+2.4% | -$56.4M-35.7% | -$58.5M-39.5% |
| EPS (Basic) | $4.93+578.6% | -$0.81-55.8% | -$0.79-17.9% | -$0.83-10.7% | -$1.03-53.7% | -$0.52+26.8% | -$0.67+11.8% | -$0.75+2.6% |
| EPS (Diluted) | $4.73+559.2% | -$0.81-55.8% | -$0.79-17.9% | -$0.83-10.7% | -$1.03-53.7% | -$0.52+26.8% | -$0.67 | -$0.75+2.6% |
| Diluted Shares (Avg) | 116M+38.0% | 111M+32.4% | 110M+31.7% | N/A | 84M+15.6% | 84M+34.5% | 84M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
NRIX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B+128.8% | $535.5M-9.5% | $636.1M+3.4% | $688.1M+2.8% | $522.5M+1.7% | $591.6M+15.8% | $615.0M+96.7% | $669.3M+88.2% |
| Current Assets | $1.1B+150.5% | $456.5M-11.4% | $554.4M-1.7% | $606.8M-2.0% | $440.6M-3.4% | $515.3M+14.5% | $563.7M+124.6% | $619.4M+109.6% |
| Cash & Equivalents | $720.2M+818.2% | $67.7M-19.7% | $71.2M-6.2% | $247.0M+124.5% | $78.4M-20.8% | $84.3M-27.9% | $75.9M+52.4% | $110.0M+101.4% |
| Short-Term Investments | $328.0M-6.4% | $375.8M-6.4% | $469.5M-0.9% | $346.0M-30.7% | $350.4M+0.4% | $401.5M+23.0% | $473.8M | $499.6M+114.2% |
| Accounts Receivable | $20.0M | N/A | N/A | $0 | N/A | $19.0M | N/A | $0 |
| Long-Term Investments | $14.8M | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0 | $0-100.0% |
| Total Liabilities | $227.0M+51.1% | $132.9M-7.7% | $155.2M+15.7% | $149.4M+4.9% | $150.2M+9.9% | $144.0M+2.6% | $134.1M-6.8% | $142.3M-8.2% |
| Current Liabilities | $130.7M+58.8% | $72.0M-4.8% | $92.2M+2.5% | $86.5M-9.8% | $82.3M-4.6% | $75.6M-6.4% | $90.0M+2.7% | $95.9M+10.2% |
| Non-Current Liabilities | $96.2M+41.8% | $60.9M-10.9% | $63.0M+42.8% | $62.9M+35.3% | $67.9M+34.5% | $68.3M+14.7% | $44.1M-21.6% | $46.5M-31.8% |
| Total Equity | $968.3M+160.1% | $402.6M-10.0% | $480.9M0.0% | $538.7M+2.2% | $372.3M-1.2% | $447.6M+20.7% | $480.9M+185.0% | $527.0M+162.8% |
| Retained Earnings | -$630.1M+31.9% | -$1.2B-40.7% | -$1.1B-37.1% | -$1.0B-35.8% | -$925.0M-36.0% | -$838.6M-32.8% | -$795.1M-35.5% | -$738.8M-35.5% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
NRIX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $615.6M+1172.8% | -$96.6M-52.9% | -$71.9M-17.7% | -$67.8M-39.1% | -$57.4M-36.1% | -$63.2M-59.1% | -$61.1M-45.6% | -$48.8M-282.7% |
| Depreciation & Amortization | $2.1M+5.5% | $2.3M+0.6% | $2.2M-6.6% | $2.1M-16.8% | $2.0M-15.3% | $2.2M-3.8% | $2.4M+14.9% | $2.5M+31.8% |
| Stock-Based Compensation | N/A | N/A | $9.4M+7.8% | N/A | N/A | N/A | $8.7M+11.5% | N/A |
| Capital Expenditures | $1.4M-48.7% | $1.9M-27.6% | $1.0M-70.0% | $5.1M+143.8% | $2.7M+15.5% | $2.7M+38.1% | $3.5M+20.8% | $2.1M-18.6% |
| Free Cash Flow | $614.2M+1122.1% | -$98.5M-49.6% | -$73.0M-13.0% | -$73.0M-43.5% | -$60.1M-35.0% | -$65.8M-58.1% | -$64.6M-44.0% | -$50.9M-311.0% |
| Investing Cash Flow | $31.6M-37.4% | $93.0M+30.1% | -$123.8M-585.0% | $346K+100.2% | $50.5M+336.5% | $71.5M+154.6% | $25.5M-28.1% | -$140.8M-879.7% |
| Financing Cash Flow | $5.2M+346.7% | $66K+1000.0% | $20.0M+1256.1% | $236.0M+17.7% | $1.2M-97.5% | $6K-100.0% | $1.5M-9.3% | $200.5M+2864485.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
NRIX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 83.1% | -1041.7% | -1479.4% | -612.0% | -1157.6% | -109.7% | -340.7% | -486.7% |
| Net Margin | 81.7% | -990.1% | -1394.3% | -576.1% | -1094.8% | -98.7% | -305.4% | -440.8% |
| Return on Equity | 56.8%+80.0pp | -22.2%-12.5pp | -18.1%-6.4pp | -14.5%-3.4pp | -23.2%-10.2pp | -9.7%+2.3pp | -11.7%+12.9pp | -11.1%+9.8pp |
| Return on Assets | 46.0%+62.5pp | -16.7%-9.4pp | -13.7%-4.5pp | -11.4%-2.6pp | -16.5%-7.0pp | -7.3%+1.4pp | -9.2%+4.1pp | -8.8%+3.0pp |
| Current Ratio | 8.44+3.1x | 6.34-0.5x | 6.01-0.3x | 7.02+0.6x | 5.35+0.1x | 6.82+1.2x | 6.26+3.4x | 6.46+3.1x |
| Debt-to-Equity | 0.23-0.2x | 0.330.0x | 0.320.0x | 0.280.0x | 0.400.0x | 0.32-0.1x | 0.28-0.6x | 0.27-0.5x |
| Asset Turnover | 0.56+0.5x | 0.02-0.1x | 0.010.0x | 0.020.0x | 0.020.0x | 0.07+0.1x | 0.030.0x | 0.020.0x |
| FCF Margin | 91.3% | -1089.3% | -1167.0% | -537.4% | -761.3% | -149.4% | -349.9% | -382.8% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. NRIX | FY2025 | $84.0M | -$264.5M | N/A | $2.6B | 54/100 |
| Relay Therapeutics, Inc. RLAY | FY2025 | $15.4M | -$276.5M | N/A | $3.7B | 50/100 |
| Rigel Pharmaceuticals Inc. (New) RIGL | FY2025 | $294.3M | $367.0M | N/A | $874.6M | 62/100 |
| ArriVent BioPharma, Inc. AVBP | FY2025 | N/A | -$166.3M | N/A | $798.8M | — |
| Day One Biopharmaceuticals, Inc. DAWN | FY2025 | $158.2M | N/A | N/A | $2.2B | 51/100 |
| Prime Medicine, Inc. PRME | FY2025 | $4.6M | -$201.1M | N/A | $567.7M | 57/100 |
Where Nurix Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Nurix Therapeutics, Inc.'s annual revenue?
Nurix Therapeutics, Inc. (NRIX) reported $84.0M in total revenue for fiscal year 2025. This represents a 54.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nurix Therapeutics, Inc.'s revenue growing?
Nurix Therapeutics, Inc. (NRIX) revenue grew by 54.0% year-over-year, from $54.5M to $84.0M in fiscal year 2025.
Is Nurix Therapeutics, Inc. profitable?
No, Nurix Therapeutics, Inc. (NRIX) reported a net income of -$264.5M in fiscal year 2025.
What is Nurix Therapeutics, Inc.'s EBITDA?
Nurix Therapeutics, Inc. (NRIX) had EBITDA of -$276.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nurix Therapeutics, Inc.'s return on equity (ROE)?
Nurix Therapeutics, Inc. (NRIX) has a return on equity of -49.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nurix Therapeutics, Inc.'s free cash flow?
Nurix Therapeutics, Inc. (NRIX) recorded an outflow of $263.5M in free cash flow during fiscal year 2025. This represents a -44.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nurix Therapeutics, Inc.'s operating cash flow?
Nurix Therapeutics, Inc. (NRIX) recorded an outflow of $249.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Nurix Therapeutics, Inc.'s total assets?
Nurix Therapeutics, Inc. (NRIX) had $688.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nurix Therapeutics, Inc.'s capital expenditures?
Nurix Therapeutics, Inc. (NRIX) invested $14.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nurix Therapeutics, Inc. spend on research and development?
Nurix Therapeutics, Inc. (NRIX) invested $316.9M in research and development during fiscal year 2025.
What is Nurix Therapeutics, Inc.'s current ratio?
Nurix Therapeutics, Inc. (NRIX) had a current ratio of 7.02 as of fiscal year 2025, which is generally considered healthy.
What is Nurix Therapeutics, Inc.'s debt-to-equity ratio?
Nurix Therapeutics, Inc. (NRIX) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nurix Therapeutics, Inc.'s return on assets (ROA)?
Nurix Therapeutics, Inc. (NRIX) had a return on assets of -38.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nurix Therapeutics, Inc.'s P/E ratio?
Nurix Therapeutics, Inc. (NRIX) trades at 8.8x earnings, its market capitalization divided by net income of $294.9M net income, trailing 12 months to August 31, 2026. The market capitalization is $2.6B as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Nurix Therapeutics, Inc.'s price-to-sales ratio?
Nurix Therapeutics, Inc. (NRIX) trades at 3.7x sales, its market capitalization divided by revenue of $701.9M revenue, trailing 12 months to August 31, 2026. The market capitalization is $2.6B as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Nurix Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Nurix Therapeutics, Inc. (NRIX) held $592.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $249.5M over that year. Dividing the one by the other, the reported balance equals about 29 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Nurix Therapeutics, Inc.'s Altman Z-Score?
Nurix Therapeutics, Inc. (NRIX) has an Altman Z-Score of 8.00, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nurix Therapeutics, Inc.'s Piotroski F-Score?
Nurix Therapeutics, Inc. (NRIX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nurix Therapeutics, Inc.'s earnings high quality?
Nurix Therapeutics, Inc. (NRIX) reported a net loss of $264.5M while operations used $249.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Nurix Therapeutics, Inc.?
Nurix Therapeutics, Inc. (NRIX) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.